BOA1

Featured post

#Avian #Influenza #H7N9 in #China: Preventing the Next #SARS (@WHO, Apr. 2 ‘17)

  Title : #Avian #Influenza #H7N9 in #China: Preventing the Next #SARS. Subject : Avian Influenza, H7N9 subtype (Asian Lineage), poultry e...

18 Oct 2016

#PrEP for #HIV #prevention in #Europe (@ECDC_EU, summary)

 

Title: #PrEP for #HIV #prevention in #Europe.

Subject: HIV/AIDS, antiviral drugs for pre-exposure prophylaxis in at risk populations; ECDC update.

Source: European Centre for Disease Prevention and Control (ECDC), full PDF file: (LINK). Summary.

Code: [     ]

_____

ECDC EVIDENCE BRIEF

Pre-exposure prophylaxis for HIV prevention in Europe

___

Suggested citation: European Centre for Disease Prevention and Control. Evidence brief: Pre-exposure prophylaxis for HIV prevention in Europe. Stockholm: ECDC; 2016.

© European Centre for Disease Prevention and Control, Stockholm, 2016

 

Key messages

  • Pre-exposure prophylaxis (PrEP) can reduce the risk of infections in HIV-seronegative persons at substantial risk, as long as it is taken as prescribed.
  • Use of PrEP as an additional prevention option has the potential to reduce HIV transmission and contribute to reversing the increase in new infections in Europe.
  • France is the only country in Europe currently providing PrEP through public health services, but a number of other countries are implementing or planning to implement PrEP demonstration projects.
  • Use of antiretroviral medication for PrEP has been approved in the European Union, but countries cite the cost of drugs as a key barrier to provision of PrEP by public health services.

 

Introduction

  • Pre-exposure prophylaxis (PrEP) is the use of an antiretroviral medication by people who are uninfected to prevent the acquisition of HIV.
  • The efficacy of PrEP has been shown in a number of randomised controlled trials including iPREX (Pre-exposure Prophylaxis Initiative), Partners PrEP, PROUD and ANRS-IPERGAY (French Research Agency trial) [1-4’].
  • Two of these trials were conducted in Europe – PROUD in the United Kingdom and ANRS-IPERGAY in France. 
  • In 2015, the World Health Organization recommended that PrEP should be offered as an additional prevention option for people at substantial risk of HIV infection based on the results of these trials [5].
  • Current guidelines recommend that PrEP be made available to populations at high risk of acquiring HIV infection [5,6].
  • Eligibility criteria may need to be adapted as population groups at high risk of HIV differ between countries in Europe.
  • PrEP is a rapidly evolving area with new regulations and guidance being developed to reflect new available evidence.
  • In July 2016, the European Medicines Agency recommended granting market authorisation in the European Union for use of the antiretroviral medication Truvada1 for PrEP, to reduce the risk of sexually-acquired HIV infection in adults at high risk [7].
  • This recommendation was approved by the European Commission in August 2016.
  • This evidence brief summarises key issues and priorities for action in Europe.
  • It draws on data on PrEP reported to ECDC by 47 countries for Dublin Declaration monitoring in early 2016, and refers to subsequent developments as of August 2016.

(…)

___

1) Any mention of commercial product or service within ECDC publications is for information only. It should not be displayed in a manner which suggests endorsement by ECDC. For more information see http://ecdc.europa.eu/en/pages/legalnotice.aspx 

-

Keywords: PrEP; HIV/AIDS; ECDC; European Region; Updates.

-----